Study of Syntenin Evaluation of the Efficacy of Neoadjuvant Chemotherapy in Patients with Negative Breast Cancer

Yu Xiaoting; Tang Jie; Jiang Fangqian

doi:10.3969/j.issn.1004-5775.2025.04.012

Abstract：Objective:To study the expression characteristics and clinical features of ligand protein syndecan-binding protein(Syntenin)in triple-negative breast cancer(TNBC),and evaluate whether Syntenin protein can serve as a biomarker for NAC efficacy.Methods:A total of 132 patients with triple-negative breast cancer who underwent neoadjuvant therapy from December 2020 to December 2021 were selected.According to the expression level of Syntenin,60 cases were divided into negative group,and 72 cases were positive group.Clinical data of menstrual status,tumor diameter,lymph node stage,TNM stage and Ki67 expression were collected for statistical analysis.Results:Before NAC,there were 72 patients in positive group and 60 patients in negative group.After NAC,the number of patients decreased to 37 in the positive group and increased to 95 in the negative group.The expression rate of Syntenin before and after NAC was significantly different between the two groups(x2=19.142,P＜0.00l).Before NAC,there was no significant difference in menopausal status between the two groups(x2=0.666,P＞0.05).There were significant differences in tumor diameter,lymph node stage,TNM stage and Ki67 index between the two groups(x2=22.172,2.626.8.765.4.440;P＜0.05).After NAC,there were no significant differences in menopausal status,tumor diameter,lymph node stage and TNM stage between the two groups(x2=0.241,2.347,0.845,0.233;P＞0.05).There was significant difference in Ki67 index between the two groups(x2=4.067,P＜0.05).There were significant differences in the expression of pre-NAC Syntenin,tumor diameter and lymph node staging(x2=7.557,7.137,4.898;P＜0.05).Conclusion:Syntenin expression decreases significantly after NAC,and is closely related to tumor diameter,lymph node stage and Ki67 index.Monitoring Syntenin expression during NAC can be used as a biomarker of NAC efficacy.